KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Equity Ratio (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Equity Ratio for 16 consecutive years, with 0.05 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Equity Ratio rose 7274.95% year-over-year to 0.05, compared with a TTM value of 0.05 through Jun 2025, up 7274.95%, and an annual FY2024 reading of 0.02, up 127.46% over the prior year.
  • Equity Ratio was 0.05 for Q2 2025 at Alnylam Pharmaceuticals, up from 0.03 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.28 in Q1 2021 and bottomed at 0.12 in Q2 2023.
  • Average Equity Ratio over 5 years is 0.04, with a median of 0.01 recorded in 2024.
  • The sharpest move saw Equity Ratio plummeted 326.94% in 2023, then soared 7274.95% in 2025.
  • Year by year, Equity Ratio stood at 0.16 in 2021, then plummeted by 127.63% to 0.04 in 2022, then dropped by 29.13% to 0.06 in 2023, then surged by 127.46% to 0.02 in 2024, then soared by 246.85% to 0.05 in 2025.
  • Business Quant data shows Equity Ratio for ALNY at 0.05 in Q2 2025, 0.03 in Q1 2025, and 0.02 in Q4 2024.